Cargando…

Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies

BACKGROUND: Amodiaquine is a 4-aminoquinoline antimalarial used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine. Oral amodiaquine can cause bradycardia, hypotension, and electrocardiograph (ECG...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Xin Hui S, Chotsiri, Palang, Capel, Rebecca A, Pike, James, Hanboonkunupakarn, Borimas, Lee, Sue J, Hanafiah, Maryam, Win, Yan Naung, Cremer, Maegan, Kiechel, Jean-René, Ogutu, Bernhards, Taylor, Walter RJ, Burton, Rebecca-Ann B, Tarning, Joel, White, Nicholas J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614325/
https://www.ncbi.nlm.nih.gov/pubmed/36256474
http://dx.doi.org/10.1111/bcp.15569
_version_ 1783605591853236224
author Chan, Xin Hui S
Chotsiri, Palang
Capel, Rebecca A
Pike, James
Hanboonkunupakarn, Borimas
Lee, Sue J
Hanafiah, Maryam
Win, Yan Naung
Cremer, Maegan
Kiechel, Jean-René
Ogutu, Bernhards
Taylor, Walter RJ
Burton, Rebecca-Ann B
Tarning, Joel
White, Nicholas J
author_facet Chan, Xin Hui S
Chotsiri, Palang
Capel, Rebecca A
Pike, James
Hanboonkunupakarn, Borimas
Lee, Sue J
Hanafiah, Maryam
Win, Yan Naung
Cremer, Maegan
Kiechel, Jean-René
Ogutu, Bernhards
Taylor, Walter RJ
Burton, Rebecca-Ann B
Tarning, Joel
White, Nicholas J
author_sort Chan, Xin Hui S
collection PubMed
description BACKGROUND: Amodiaquine is a 4-aminoquinoline antimalarial used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine. Oral amodiaquine can cause bradycardia, hypotension, and electrocardiograph (ECG) QT interval prolongation in animals and humans but the relationship of these changes to drug concentrations is not well characterised. METHODS: We conducted a secondary analysis of data from a pharmacokinetic study of the cardiac safety of amodiaquine (10mg/kg/day over 3 days) in 54 Kenyan adults (≥18 years) with uncomplicated malaria. Non-linear mixed effects modelling was used to assess amodiaquine and desethylamodiaquine concentration-effect relationships for vital sign (pulse rate, blood pressure) and ECG interval (QT, QRS, PR) outcomes. We also measured the spontaneous beating heart rate after cumulative dosing of amodiaquine and desethylamodiaquine in isolated mouse atrial preparations. FINDINGS: Amodiaquine and desethylamodiaquine caused concentration-dependent mean decreases in pulse rate (1.9beats/minute per 100nmol/L), supine systolic blood pressure (1.7mmHg per 100nmol/L), erect systolic blood pressure (1.5mmHg per 100nmol/L), and erect diastolic blood pressure (1.4mmHg per 100nmol/L). The mean QT interval prolongation was 1.4milliseconds per 100nmol/L irrespective of correction factor used after adjustment for residual heart rate dependency. There was no significant independent effect of drug concentration on postural change in blood pressure or PR and QRS intervals. In mouse atria, the spontaneous beating rate was significantly reduced by amodiaquine (n=7) and desethylamodiaquine (n=8) at 3μmol/litre (amodiaquine: 10% ± 2%; desethylamodiaquine: 12% ± 3%) and 10μmol/litre (amodiaquine: 50% ± 7%; desethylamodiaquine: 46% ± 6%) concentrations with no significant difference in potency between the two compounds. INTERPRETATION: Amodiaquine and desethylamodiaquine have concentration-dependent effects on heart rate, blood pressure, and ventricular repolarisation.
format Online
Article
Text
id pubmed-7614325
institution National Center for Biotechnology Information
language English
publishDate 2023
record_format MEDLINE/PubMed
spelling pubmed-76143252023-03-16 Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies Chan, Xin Hui S Chotsiri, Palang Capel, Rebecca A Pike, James Hanboonkunupakarn, Borimas Lee, Sue J Hanafiah, Maryam Win, Yan Naung Cremer, Maegan Kiechel, Jean-René Ogutu, Bernhards Taylor, Walter RJ Burton, Rebecca-Ann B Tarning, Joel White, Nicholas J Br J Clin Pharmacol Article BACKGROUND: Amodiaquine is a 4-aminoquinoline antimalarial used extensively for the treatment and prevention of malaria. Orally administered amodiaquine is largely converted to the active metabolite desethylamodiaquine. Oral amodiaquine can cause bradycardia, hypotension, and electrocardiograph (ECG) QT interval prolongation in animals and humans but the relationship of these changes to drug concentrations is not well characterised. METHODS: We conducted a secondary analysis of data from a pharmacokinetic study of the cardiac safety of amodiaquine (10mg/kg/day over 3 days) in 54 Kenyan adults (≥18 years) with uncomplicated malaria. Non-linear mixed effects modelling was used to assess amodiaquine and desethylamodiaquine concentration-effect relationships for vital sign (pulse rate, blood pressure) and ECG interval (QT, QRS, PR) outcomes. We also measured the spontaneous beating heart rate after cumulative dosing of amodiaquine and desethylamodiaquine in isolated mouse atrial preparations. FINDINGS: Amodiaquine and desethylamodiaquine caused concentration-dependent mean decreases in pulse rate (1.9beats/minute per 100nmol/L), supine systolic blood pressure (1.7mmHg per 100nmol/L), erect systolic blood pressure (1.5mmHg per 100nmol/L), and erect diastolic blood pressure (1.4mmHg per 100nmol/L). The mean QT interval prolongation was 1.4milliseconds per 100nmol/L irrespective of correction factor used after adjustment for residual heart rate dependency. There was no significant independent effect of drug concentration on postural change in blood pressure or PR and QRS intervals. In mouse atria, the spontaneous beating rate was significantly reduced by amodiaquine (n=7) and desethylamodiaquine (n=8) at 3μmol/litre (amodiaquine: 10% ± 2%; desethylamodiaquine: 12% ± 3%) and 10μmol/litre (amodiaquine: 50% ± 7%; desethylamodiaquine: 46% ± 6%) concentrations with no significant difference in potency between the two compounds. INTERPRETATION: Amodiaquine and desethylamodiaquine have concentration-dependent effects on heart rate, blood pressure, and ventricular repolarisation. 2023-03-01 2022-11-08 /pmc/articles/PMC7614325/ /pubmed/36256474 http://dx.doi.org/10.1111/bcp.15569 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/) International license.
spellingShingle Article
Chan, Xin Hui S
Chotsiri, Palang
Capel, Rebecca A
Pike, James
Hanboonkunupakarn, Borimas
Lee, Sue J
Hanafiah, Maryam
Win, Yan Naung
Cremer, Maegan
Kiechel, Jean-René
Ogutu, Bernhards
Taylor, Walter RJ
Burton, Rebecca-Ann B
Tarning, Joel
White, Nicholas J
Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies
title Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies
title_full Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies
title_fullStr Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies
title_full_unstemmed Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies
title_short Cardiovascular Concentration-Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre-clinical Studies
title_sort cardiovascular concentration-effect relationships of amodiaquine and its metabolite desethylamodiaquine: clinical and pre-clinical studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614325/
https://www.ncbi.nlm.nih.gov/pubmed/36256474
http://dx.doi.org/10.1111/bcp.15569
work_keys_str_mv AT chanxinhuis cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies
AT chotsiripalang cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies
AT capelrebeccaa cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies
AT pikejames cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies
AT hanboonkunupakarnborimas cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies
AT leesuej cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies
AT hanafiahmaryam cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies
AT winyannaung cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies
AT cremermaegan cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies
AT kiecheljeanrene cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies
AT ogutubernhards cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies
AT taylorwalterrj cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies
AT burtonrebeccaannb cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies
AT tarningjoel cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies
AT whitenicholasj cardiovascularconcentrationeffectrelationshipsofamodiaquineanditsmetabolitedesethylamodiaquineclinicalandpreclinicalstudies